Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantheus Holdings, Inc. filings document its radiopharmaceutical operating results, Nasdaq-listed common stock, governance and material corporate events. Form 8-K reports furnish quarterly and annual financial results, business updates, FDA-related disclosures for diagnostic and therapeutic radiopharmaceutical products, share repurchase authorization, and executive and board changes.
Proxy materials describe director elections, executive compensation, shareholder voting matters and equity incentive plan approvals. The filings also cover material modifications to security holder rights, Regulation FD disclosures and capital-structure details relevant to common stock issued by a public radiopharmaceutical company.
Lantheus Holdings presents an in-depth annual update highlighting a major strategic shift toward radiopharmaceutical oncology and precision diagnostics. The company relies on key products PYLARIFY, DEFINITY and Neuraceq, supported by AI tools aBSI and aPROMISE and CDMO services acquired with Evergreen.
In 2025–2026, Lantheus executed significant portfolio moves, including selling its SPECT business to SHINE Technologies for consideration of up to $155.0 million, acquiring Life Molecular for $352.9 million in upfront cash plus up to $400.0 million in milestones, and buying Evergreen for $276.4 million upfront with up to $727.5 million in potential milestones.
The report notes a leadership transition with Mary Anne Heino becoming CEO on January 1, 2026, and outlines an extensive pipeline in prostate cancer and Alzheimer’s disease, including MK-6240, NAV-4694, LNTH-2501, LNTH-240x assets and PNT2003. It also summarizes numerous risks: dependence on PYLARIFY and DEFINITY, reimbursement and regulatory uncertainties, integration of acquisitions, patent and ANDA litigation around PNT2003, and competition from large global radiopharmaceutical and imaging players.
Lantheus Holdings reported fourth-quarter 2025 revenue of $406.8 million, up 4.0%, and full-year revenue of $1.54 billion. GAAP diluted EPS was $0.82 for the quarter and $3.41 for 2025, while adjusted diluted EPS reached $1.67 in Q4 and $6.08 for the year.
PYLARIFY sales were $240.2 million in the quarter, down 9.7%, while DEFINITY slipped 1.0% to $85.3 million and Neuraceq contributed $31.0 million. The company repurchased $100 million of stock in Q4 and about $300 million for the year, completed acquisitions of Life Molecular Imaging and Evergreen Theragnostics, and exited its legacy SPECT business. Lantheus is sharpening its focus on innovative PET radiodiagnostics and issued 2026 guidance of $1.4–$1.45 billion in revenue and adjusted diluted EPS of $5.00–$5.25.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 5,707,247 shares of Lantheus Holdings, Inc. common stock, representing 8.6% of the class as of 12/31/2025.
The filing states that various Janus Henderson asset management subsidiaries exercise shared voting and shared dispositive power over these shares on behalf of their clients, referred to as Managed Portfolios. The Managed Portfolios, not Janus Henderson, have the right to receive all dividends and sale proceeds, and no individual Managed Portfolio holds more than five percent of Lantheus’ common stock. Janus Henderson certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Lantheus.
Morgan Stanley filed an amended Schedule 13G showing updated ownership in Lantheus Holdings, Inc. common stock as of December 31, 2025. Morgan Stanley reports beneficial ownership of 1,640,837 shares, representing 2.5% of the class, with all voting and dispositive power shared among its reporting units.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 936,899 shares, or 1.4% of the class, with shared voting and dispositive power. Both reporting persons state they have ceased to be beneficial owners of more than five percent of Lantheus’s common stock and certify that the holdings are in the ordinary course of business and not for influencing control.
Farallon-affiliated funds and managers report a significant passive stake in Lantheus Holdings, Inc. As of the event date of 12/31/2025, the Farallon reporting group discloses beneficial ownership of 5,427,479 shares of Lantheus common stock, representing 8.2% of the outstanding Shares.
The Amendment notes internal leadership changes at Farallon entities. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased to be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen became a member and manager of several Farallon general partners and may be deemed a beneficial owner. The group certifies the holdings are not for changing or influencing control of Lantheus.
A shareholder has filed a notice of proposed sale of 6,713 shares of common stock, with an aggregate market value of 449,570.29. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/02/2026. The issuer has 66,311,779 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting and employee stock purchase plan transactions between 03/03/2022 and 09/12/2025. The filing also lists prior sales over the past three months by Paul M. Blanchfield, including multiple common stock sales with stated gross proceeds.
Lantheus Holdings’ Chief Commercial Officer reported small changes in personal ownership of the company’s common stock related to transactions on December 15, 2024 and December 15, 2025. The transactions, each coded "F," involved the disposition of 356 shares at $93.48 and 368 shares at $66.57.
After the December 2024 transaction, the officer beneficially owned 25,055 shares. After the December 2025 transaction, beneficial ownership increased to 39,094 shares, which includes 143 shares acquired under the LNTH employee stock purchase plan on March 13, 2025, and 95 shares acquired under the same plan on September 12, 2025.
Lantheus Holdings, Inc. (LNTH) reported an insider equity award for a director and Executive Chair. On November 17, 2025, the reporting person received 14,285 restricted stock units that will vest in full on November 17, 2026. The filing shows direct ownership of 332,935 shares of common stock after this grant, plus additional indirect holdings through several trusts.
The insider also received a stock option covering 26,325 shares of Lantheus common stock with an exercise price of $52.50 per share. This option vests in full on November 17, 2026 and expires on November 17, 2035. Following this transaction, the reporting person beneficially owns 26,325 stock options in addition to the reported common stock positions.
Lantheus Holdings (LNTH) announced CEO transition arrangements. Effective November 6, 2025, the company entered into a Consulting Agreement with CEO Brian Markison and a Retirement and Separation Agreement. Mr. Markison will retire on December 31, 2025 and then serve as an advisor from January 1, 2026 through March 31, 2026, with an option to extend.
Under the Retirement Agreement, the company will continue his base salary through the Retirement Date. Within 60 days of December 31, 2025, he will receive a lump sum equal to his earned annual cash bonus for 2025, if any, based on actual company performance as determined in the ordinary course. Under the Consulting Agreement, he will receive an advisory fee of $83,333 per month. His outstanding equity awards will continue to vest through December 31, 2025 and thereafter follow the retirement features described in the company’s March 21, 2025 proxy statement.
Lantheus Holdings (LNTH) reported Q3 2025 results. Revenue was $384.0 million and diluted EPS was $0.41 as operating income declined to $43.6 million, reflecting higher sales, G&A, and R&D expenses and a higher effective tax rate of 34.5%.
Revenue mix shifted: PYLARIFY was $240.6 million (down year over year), DEFINITY rose to $81.8 million, and Neuraceq contributed $20.4 million following the Life Molecular acquisition. Year-to-date operating cash flow reached $300.0 million, while investing cash outflows reflected acquisitions of Evergreen ($268.9 million) and Life Molecular ($309.0 million). The company repurchased about $201.2 million of common stock year to date.
Cash and cash equivalents were $382.0 million versus $912.8 million at year-end, with intangibles and goodwill increasing from recent deals. LNTH classified its SPECT business as held for sale, with $76.6 million of assets and $28.6 million of liabilities. The $575.0 million 2.625% convertible notes remain outstanding; the $750.0 million revolving credit facility had no borrowings.